Vaxart, Inc.
Biological Products, (No Diagnostic Substances) · 310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
공식 등기 데이터
0팔로워
2004설립
Vaxart, Inc. 소개
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc.
Source: Wikipedia
산업Biological Products, (No Diagnostic Substances)
본사310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
설립2004
법적 형태C Corporation
상태운영 중
특허특허 58건
ANTIBODIES TARGETING GII GENOTYPES OF HUMAN NOROVIRUSWO2025255258A3 · 2026
ANTIBODIES TARGETING GII GENOTYPES OF HUMAN NOROVIRUSWO2025255258A2 · 2025
주요 수치
법적 정보
| 법인명 | Vaxart, Inc. |
|---|---|
| 법적 형태 | C Corporation |
| SEC CIK | 72444SEC EDGAR에서 보기 ↗ |
| EIN | 59-1212264 |
| 업종 코드(SIC) | 2836 |
| 등기 주소 | 310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA |
| 상태 | 운영 중 |
출처: SEC EDGAR · 2026년 10월 15일 업데이트
연락처 및 링크
위치
310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
귀하의 회사인가요?
이 페이지를 무료로 신청하여 로고, 제품, 사진, 채용 공고를 추가하고 리뷰에 답변하세요.
이 페이지 신청